◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY
Protagonist Therapeutics, Inc. (PTGX) EPS 2021–2025
DATA UPDATED 2026-07-21
Protagonist Therapeutics, Inc. annual earnings per share (EPS) for fiscal 2025 was $-2.05, compared with $4.23 in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
PTGX Annual EPS
| EPS (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|
| Diluted EPS | ($2M) | $4M | ($1M) | ($3M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
PTGX Quarterly EPS
| EPS (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|
| Diluted EPS | $0M | ($1M) | ($1M) | ($1M) | ($0M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More PTGX metrics: Revenue · Operating Income · Net Income · Free Cash Flow
All PTGX financial statements → Interactive PTGX charts →
About TickerBase · Data methodology & sources
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.